Who are Brivanib 800 mg, QD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): pirfenidone or nintedanib, Lenvatinib + losartan, AL3818 Capsule, Len-TACE, Adjuvant tislelizumab plus lenvatinib, Lenvatinib, sintilimab plus TACE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brivanib-800-mg-qd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Brivanib 800 mg, QD — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brivanib 800 mg, QD (Brivanib 800 mg, QD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual FGFR/VEGFR inhibitor. Area: Oncology.

phase 2 Dual FGFR/VEGFR inhibitor FGFR, VEGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Brivanib 800 mg, QD (Brivanib 800 mg, QD) — Zai Lab (Shanghai) Co., Ltd.. Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Brivanib 800 mg, QD TARGET	Brivanib 800 mg, QD	Zai Lab (Shanghai) Co., Ltd.	phase 2	Dual FGFR/VEGFR inhibitor	FGFR, VEGFR
pirfenidone or nintedanib	pirfenidone or nintedanib	Hospices Civils de Lyon	marketed	Antifibrotic agent	Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases
Lenvatinib + losartan	Lenvatinib + losartan	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist	FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
AL3818 Capsule	AL3818 Capsule	Advenchen Laboratories Nanjing Ltd.	phase 3	Multi-targeted tyrosine kinase inhibitor	FGFR, VEGFR, and other receptor tyrosine kinases
Len-TACE	Len-TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor (combined with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT
Adjuvant tislelizumab plus lenvatinib	Adjuvant tislelizumab plus lenvatinib	Guangxi Medical University	phase 3	PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination	PD-1 (tislelizumab); FGFR, VEGFR, RET, KIT (lenvatinib)
Lenvatinib, sintilimab plus TACE	Lenvatinib, sintilimab plus TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor + PD-1 inhibitor + locoregional chemotherapy	FGFR, VEGFR, RET, KIT (lenvatinib); PD-1 (sintilimab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual FGFR/VEGFR inhibitor class)

Zai Lab (Shanghai) Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brivanib 800 mg, QD — Competitive Intelligence Brief. https://druglandscape.com/ci/brivanib-800-mg-qd. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab